Forest Labs submits cariprazine for FDA review

Forest Labs submits potential antipsychotic treatment cariprazine for FDA review

Associated Press

NEW YORK (AP) -- Forest Laboratories Inc. has submitted the potential oral schizophrenia and bipolar treatment cariprazine to the Food and Drug Administration for approval.

Cariprazine was developed by Hungarian drugmaker Gedeon Richter Plc. and licensed to New York-based Forest in the United States and Canada. It aims to treat bipolar I disorder, which is also known as manic-depressive illness and characterized by unusual shifts in a person's mood, energy level or ability to carry out daily tasks.

Schizophrenia is a chronic condition that can include hallucinations, delusions and social withdrawal.

Cariprazine's side effects include restlessness, tremors, an upset stomach, and vomiting.

Forest Laboratories shares closed at $33.52 on Tuesday. They have ranged from $28.47 to $37.70 over the past year.

View Comments (0)